RE: Keytruda Gets Second FDA Approval for Endometrial Cancer March 23, 2022 The FDA has ap23 Mar 2022 07:13
The approval was based on phase 2 study results in 90 patients who received 200 mg of Keytruda intravenously every three weeks. Out of 41 patients who responded to the treatment, 68 percent had responses lasting 12 months or longer and 44 percent had responses lasting 24 months or longer.
Impressive GLA